Darcy Lewis

As part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.

A phase 2 study of surufatinib in patients with biliary tract carcinoma showed some benefit and a larger phase 3 study is underway.

Results from the phase 3 JUPITER-02 trial show that oncologists can extend progression-free survival in patients with nasopharyngeal carcinoma by adding toripalimab to chemotherapy.

Ensartinib, an investigational ALK inhibitor, significantly extended progression-free survival versus crizotinib in patients with advanced disease in the phase 3 eXalt3 randomized clinical trial.

Genomic testing has grown in importance as the number of targeted anticancer therapies rises. Early genomic testing can help to guide treatment choices.

FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.

When patients with myelofibrosis who required hematopoietic stem cell transplant received a conditioning regimen of thiotepa, busulfan, and fludarabine along with 2 two alkylating agents, the subsequent transplants were nearly all successful.

Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.

The frequency of mutations in patients with mantle cell lymphoma has a tendency to increase at clinical turning points like disease relapse and progression compared with at the time of diagnosis, according to a systemic review and meta-analysis.

“What we’re trying to do is move toward more personalized precision medicine based on what actually happens inside the tumor."

Four cycles of R-CHOP alone should be the new standard approach to limited-stage disease for the majority of patients with diffuse large B-cell lymphoma. That’s the conclusion of a new study that used positron emission tomography–directed treatment approaches to assess the outcomes and toxicity associated with the current standard of care.

Lenvatinib may benefit patients with advanced hepatocellular carcinoma with second- or later-line therapies and a high burden of intrahepatic lesions.

A post-hoc analysis of the phase III ZETA trial shows that vandetanib improved PFS in medullary thyroid cancer.

A pooled analysis of phase 3 clinical trials in advanced renal cell carcinoma showed that combination immunotherapy can reduce toxicity compared with sunitinib.

“In this case the detection of an expressed CCDC6-RET gene fusion in a tumor metastasis by RNA-based NGS suggested that RET inhibition might be an effective treatment option."

Long-term data from a phase Ib/II trial of the BTK inhibitor acalabrutinib were recently published. Acalabrutinib appears to evoke durable responses with good safety and efficacy.

Patients with relapsed or refractory chronic lymphocytic leukemia who received a higher dose of CAR T cells, achieved complete responses, regardless of cell dose, which was highly correlated with long-term survival.

Safety data from the phase III EMBRACA trial were recently published. Talazoparib appears to be safe with manageable toxicities in patients with germline BRCA-mutated HER2-negative advanced breast cancer.

The anti-PD-1 inhibitor camrelizumab showed antitumor activity in pretreated Chinese patients with advanced hepatocellular carcinoma and displayed manageable toxicities, according to a recent paper in Lancet Oncology.

An updated analysis from the ALCYONE trial has found that adding daratumumab to a standard-of-care regimen significantly prolonged survival in patients with transplant-ineligible multiple myeloma, according to a recent paper in The Lancet.

The addition of 6 months of oral daily enzalutamide to standard salvage radiation and hormone therapy is safe and may improve prostate cancer remission rates at 2 and 3 years postoperatively among patients with high-risk disease, according to a recent paper in European Urology Oncology.

A post hoc analysis of the ALTER 0303 trial has found that anlotinib, compared with placebo, extended the time patients with advanced non-small cell lung cancer had before brain metastases developed or existing brain lesions increased in size, reports a recent paper in The Oncologist.

New data from the RANGE study have found that ramucirumab combined with docetaxel confers a progression-free survival benefit in patients with platinum-refractory advanced urothelial cancer versus placebo and docetaxel in extended follow-up, according to a recent paper in Lancet Oncology.

Combining the antibody-drug conjugate polatuzumab vedotin with bendamustine and rituximab resulted in a significantly higher complete response rate in patients with transplantation-ineligible relapsed/refractory diffuse large B-cell lymphoma compared with patients who received BR alone. The international, multicenter, open-label, phase Ib/II trial also found that pola-BR reduced the risk of death by 58%, according to a recent Journal of Clinical Oncology paper.

Combining cabozantinib plus androgen-deprivation therapy as first-line therapy in patients with hormone-naïve metastatic prostate cancer yields promising clinical activity, according to the new single-arm phase II study, which was published in Clinical Cancer Research.

A subgroup analysis of Korean patients from the pooled data of two global phase II trials, AURA extension and AURA2, has found that osimertinib is as safe and effective in this subgroup of patients with pretreated EGFR-mutated advanced non-small cell lung cancer with T790M positive status as it was in the parent trials.

A new phase II study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy followed by surgery in patients with esophageal adenocarcinoma has found the combined regimen to be feasible and worthy of further study.

A new retrospective exploratory analysis has found no association between treatment with sorafenib and the development of sarcopenia among patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. However, this analysis, which was published recently in Thyroid, did find that sorafenib had a significant effect on muscle mass.

A new phase III trial has found that luspatercept reduced the severity of anemia in patients with transfusion-refractory, lower-risk myelodysplastic syndromes with ring sideroblasts. Results from the MEDALIST trial, which included data from 65 sites in 11 countries, were published recently in the New England Journal of Medicine.

Results from a phase II, open-label, multicenter study have shown that patients with heavily pretreated multiple myeloma responded to ibrutinib combined with bortezomib (Velcade) and dexamethasone.